Anti-CD59 antibody [MEM-43] (ab9182)
- Datasheet
- References (15)
- Protocols
Overview
-
Product nameAnti-CD59 antibody [MEM-43]
See all CD59 primary antibodies -
DescriptionMouse monoclonal [MEM-43] to CD59
-
Host speciesMouse
-
SpecificityCD59 antigen (human). MEM-43 identified CD59 as the new cluster on 4th HLDA Workshop. MEM-43 reacts with well defined epitope (WhO, P-53).
-
Tested applicationsSuitable for: IHC-Fr, WB, IP, Flow Cyt, ICC/IF, IHC-Pmore details
-
Species reactivityReacts with: Human
-
Immunogen
Thymocytes and T lymphocytes.
-
Positive control
- ICC/IF: Human fibrosarcoma cells. Flow Cyt: HT1080 cells.
-
General notes
When originally tested in WB, SDS was included in the sample buffer, however, feedback from one researcher has shown that it is best to omit SDS from the sample buffer.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferpH: 7.40
Preservative: 0.097% Sodium azide
Constituent: PBS -
Concentration information loading... -
Purity>95% by SDS-PAGE
-
Purification notesPurified by protein A chromatography.
-
ClonalityMonoclonal
-
Clone numberMEM-43
-
Myelomaunknown
-
IsotypeIgG2a
-
Light chain typeunknown
-
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab9182 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-Fr | Use at an assay dependent concentration. | |
| WB | Use at an assay dependent concentration. Use under non-reducing conditions. | |
| IP | Use at an assay dependent concentration. | |
| Flow Cyt | Use a concentration of 1 - 2 µg/ml. ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|
|
| ICC/IF | Use at an assay dependent concentration. PubMed: 17911601 | |
| IHC-P | Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
FunctionPotent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes. -
Involvement in diseaseDefects in CD59 are the cause of CD59 deficiency (CD59D) [MIM:612300].
-
Sequence similaritiesContains 1 UPAR/Ly6 domain.
-
Post-translational
modificationsN- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.
Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes. -
Cellular localizationCell membrane. Secreted. Soluble form found in a number of tissues.
- Information by UniProt
-
Database links
- Entrez Gene: 966 Human
- Omim: 107271 Human
- SwissProt: P13987 Human
- Unigene: 278573 Human
- Unigene: 709466 Human
- Unigene: 710641 Human
-
Alternative names
- 16.3A5 antibody
- 1F5 antibody
- 1F5 antigen antibody
see all
Images
-
![Immunocytochemistry/ Immunofluorescence - Anti-CD59 antibody [MEM-43] (ab9182)](https://www.abcam.com/ps/products/9/ab9182/Images/ab9182-283139-ab918211609.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-CD59 antibody [MEM-43] (ab9182)This image is courtesy of an anonymous Abreview.Human fibrosarcoma cells stained for CD59 (red) using ab9182 at 10 µg/ml in ICC/IF, followed by Donkey anti-Mouse Alexa 555 at 1/500 dilution.
-
![Flow Cytometry - Anti-CD59 antibody [MEM-43] (ab9182)](https://www.abcam.com/ps/products/9/ab9182/Images/CD59-Primary-antibodies-ab9182-2.jpg)
Flow Cytometry - Anti-CD59 antibody [MEM-43] (ab9182)This image is courtesy of an anonymous Abreviewab9182 staining CD59 in Human fibrosarcoma (HT1080) by Flow Cytometry. Cells were fixed with paraformaldehyde. The sample was incubated with the primary antibody,10 µg/ml in PBS, for 1 hour at 20°C. An Abcam PE-conjugated donkey polyclonal to mouse IgG ( ab7003), 5 µg/ml, was used as secondary antibody.
Protocols
References
This product has been referenced in:
- Wang Y et al. Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the a-gal xenoantigen. Oncol Lett 15:9061-9068 (2018). Read more (PubMed: 29805637) »
- Wang Y et al. CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. Oncol Lett 14:2961-2969 (2017). Read more (PubMed: 28928834) »
